Opiate and cocaine addictions: Challenge for pharmacotherapies

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 3, 1997, Pages 551-569

  Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Addiction; Caudate putamen; Cocaine; Dynorphin; Endogenous opioids; Heroin; Hypothalamus; Methadone; Nucleus accumbens; Opiates; Opioids

Indexed keywords

COCAINE; CORTICOTROPIN; DIAMORPHINE; DYNORPHIN A DERIVATIVE; ENDORPHIN; METHADONE; OPIATE; OPIATE AGONIST; OPIATE RECEPTOR;

ARTICLE; COMORBIDITY; DOPAMINERGIC SYSTEM; DRUG ADMINISTRATION; DRUG DEPENDENCE; DRUG DEVELOPMENT; GENE EXPRESSION; HEROIN DEPENDENCE; HUMAN; METHADONE TREATMENT; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE;

ANIMALS; COCAINE; DRUG THERAPY; HEROIN; HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS;

EID: 0030849326     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00440-6     Document Type: Article

References (152)

1. Barondess J. A., Beck J. C., Kreek M. J., Stimmel B. Contributors to a summary report]. Medical education and drug abuse: Report of a Macy Conference Josiah Macy:1973;. Jr. Foundation;. New York, NY.
2. Borg L., Broe D. M., Ho A., Kreek M. J. Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) program. Harris:1994;56th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 153. NIH Publ. No. 95-3883. Rockville, MD: US Government Printing Office; 1995:17.
3. Branch A. D., Unterwald E. M., Lee S. E., Kreek M. J. Quantitation of preproenkephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization procedure. Mol. Brain Res. 14:1992;231-238.
4. Bunzow J. R., Saez C., Mortrud M., Bouvier C., Williams J. T., Low M., Grandy D. K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 347:1994;284-288.
5. Burstein Y., Grady R. W., Kreek M. J., Rausen A. R., Peterson C. M. Thrombocytosis in the offspring of female mice receiving dl-methadone. Proc. Soc. Exp. Biol. Med. 164:1980;275-279.
6. Cambor R., Ho A., Bodner G., Lampert S., Kennedy J., Kreek M. J. Changes in clinical status of newly abstinent hospitalized cocaine users. Harris:1991;53rd. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 119. DHHS Publ. No. (ADM) 92-1888. Rockville, MD: US Government Printing Office; 1992:440.
7. Chen Y., Mestek A., Liu J., Hurley J. A., Yu L. Molecular cloning and functional expression of a mu opioid receptor from rat brain. Mol. Pharmacol. 44:1993;8-12.
8. Chen Y., Mestek A., Liu J., Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem. J. 295:1993;625-628.
9. Chen Y., Fan Y., Liu J., Mestek A., Tian M., Kozak C. A., Yu L. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 347:1994;279-283.
10. Chou J. Z., Pinto S., Kreek M. J., Chait B. T. Study of opioid peptides by laser desorption mass spectrometry. Harris:1992;54th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 132. DHHS Publ. No. (ADM) 93-3505. Rockville, MD: US Government Printing Office; 1993:380.
11. Chou J. Z., Kreek M. J., Chait B. T. Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin A in vitro. J. Am. Soc. Mass. Spectrom. 5:1994;10-16.
12. Chou J. Z., Maisonneuve I. M., Chait B. T., Kreek M. J. Study of dynorphin A in vivo processing in rat brain by microdialysis and matrix-assisted laser desorption mass spectrometry Harris:1993;55th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 141. NIH Publ. No. 94-3749. Rockville, MD: US Government Printing Office; 1994:240.
13. Chou J. Z., Chait B. T., Kreek M. J. Study of dynorphin A peptides in vitro processing in human blood by matrix-assisted laser desorption mass spectrometry. Harris:1994;56th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 153. NIH Publ. No. 95-3883. Rockville, MD: US Government Printing Office; 1995:252.
14. 2-17 inhibit adenylyl cyclase activity in rat caudate putamen. J. Pharmacol. Exp. Ther. 277:1996;359-365.
15. Claye L. H., Maisonneuve I. M., Yu J., Ho A., Kreek M. J. Local perfusion of dynorphin A. reduces extracellular dopamine levels in the nucleus accumbens Harris:1996;58th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph. Rockville, MD: US Government Printing Office; 1997.
16. Culpepper-Morgan J. A., Inturrisi C. E., Portenoy R. K., Foley K., Houde R. W., Marsh F., Kreek M. J. Treatment of opioid induced constipation with oral naloxone. A pilot study Clin. Pharmacol. Ther. 23:1992;90-95.
17. Cushman P., Kreek M. J. Methadone-maintained patients. Effects of methadone on plasma testosterone, FSH, LH and prolactin. N.Y. State J. Med. 74:1974;1970-1973.
18. Cushman P., Kreek M. J. Some endocrinologic observations in narcotic addicts. Zimmerman E., George R. Narcotic and the hypothalamus. 1974;161-173 Raven Press, New York.
19. Daunais J. B., Roberts D. C. S., McGinty J. F. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. NeuroReport. 4:1993;543-546.
20. Daunais J. B., McGinty J. F. Cocaine binges differentially alter striatal preprodynorphin mRNA. Mol. Brain Res. 29:1995;201-210.
21. Des Jarlais D. C., Marmor M., Cohen H., Yancovitz S., Garber J., Friedman S., Kreek M. J., Miescher A., Khuri E., Friedman S. M., Rothenberg R., Echenberg D., O'Malley P. O., Braff E., Chin J., Burtenol P., Sikes R. K. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. Morbid. Mortal. Weekly Rep. 33:1984;377-379.
22. Des Jarlais D. C., Friedman S. R., Novick D. M., Sotheran J. L., Thomas P., Yancovitz S. R., Mildvan D., Weber J., Kreek M. J., Maslansky R., Bartelme S., Spira T., Marmor M. HIV I infection among intravenous drug users in Manhattan, New York City 1977 to 1987. JAMA. 261:1989;1008-1012.
23. Dole V. P. Biochemistry of addiction. Annu. Rev. Biochem. 39:1970;821-840.
24. Dole V. P., Kreek M. J. Methadone plasma level. Sustained by a reservoir of drug in tissue Proc. Natl. Acad. Sci. USA. 70:1973;10.
25. Dole V. P., Nyswander M. E., Kreek M. J. Narcotic blockade. Arch. Intern. Med. 118:1966;304-309.
26. Evans C. J., Keith D. E. Jr., Morrison H., Magendzo K., Edwards R. H. Cloning of a delta opioid receptor by functional expression. Science. 258:1992;1952-1955.
27. Fukuda K., Kato S., Mori K., Nishi M., Takeshima H., Iwabe N., Miyata T., Houtani T., Sugimoto T. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 343:1994;42-46.
28. Goldstein A., Lowney L. T., Pal B. K. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc. Natl. Acad. Sci. USA. 68:1971;1742-1747.
29. Hachey D. L., Kreek M. J., Mattson D. H. Quantitative analysis of methadone in biological fluids using deuterium-labeled methadone and GLC-chemical-ionization mass spectrometry. J. Pharm. Sci. 66:1977;1579-1582.
30. Hahn E. F., Lahita R., Kreek M. J., Duma C., Inturrisi C. E. Naloxone radioimmunoassay. An improved antiserum J. Pharm. Pharmacol. 35:1983;833-836.
31. Harte E. H., Gutjahr C. L., Kreek M. J. Long-term persistence of dl-methadone in tissues. Clin. Res. 24:1976;623A.
32. Ho A., Cambor R., Bodner G., Kreek M. J. Intensity of craving is independent of depression in newly abstinent chronic cocaine users. Harris:1991;53rd. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 119. DHHS Publ. No. (ADM) 92-1888. Rockville, MD: US Government Printing Office; 1992:441.
33. Hurd Y. L., Herkenham M. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides. Mol. Brain Res. 16:1992;97-104.
34. Hurd Y. L., Brown E. E., Finlay J. M., Fibiger H. C., Gerfen C. R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Mol. Brain Res. 13:1992;165-170.
35. Ingoglia N. A., Dole V. P. Localization of d- and l-methadone after intraventricular injection into rat brain. J. Pharmacol. Exp. Ther. 175:1970;84-87.
36. Inturrisi C. E., Verebely K. Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther. 13:1972;923-930.
37. Inturrisi C. E., Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin. Pharmacol. Ther. 18:1972;633-637.
38. Izenwasser S., Unterwald E. M., Cote T. E., Cox B. M., Kreek M. J. Repeated, daily cocaine administration produces changes in basal and opioid-regulated adenylyl cyclase activity in rat caudate-putamen. Harris:1992;54th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 132. DHHS Publ. No. (ADM) 93-3505. Rockville, MD: US Government Printing Office; 1993:392.
39. Kennedy J. A., Hartman N., Sbriglio R., Khuri E., Kreek M. J. Metyrapone-induced withdrawal symptoms. Br. J. Addict. 85:1990;1133-1140.
40. Kieffer B. L., Befort K., Gaveriaux-Ruff C., Hirth C. G. The delta-opioid receptor. Isolation of a cDNA by expression cloning and pharmacological characterization Proc. Natl. Acad. Sci. USA. 89:1992;12048-12052.
41. Kosten T. R., Kreek M. J., Raghunath J., Kleber H. D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol. Psychiatry. 21:1986;217-220.
42. Kosten T. R., Kreek M. J., Raghunath J., Kleber H. D. A preliminary study of beta-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci. 39:1986;55-59.
43. Kosten T. R., Kreek M. J., Swift C., Carney M. K., Ferdinands L. Beta-endorphin levels in CSF during methadone maintenance. Life Sci. 41:1987;1071-1076.
44. Kosten T. R., Morgan C., Kreek M. J. Beta-endorphin levels during heroin, methadone, buprenorphine and naloxone challenges. Preliminary findings Biol. Psychiatry. 32:1992;523-528.
45. Kreek M. J. Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment. Washington:1972;171-174. DC: NAPAN-NIMH;
46. Kreek M. J. Medical safety and side effects of methadone in tolerant individuals. JAMA. 223:1973;665-668.
47. Kreek M. J. Plasma and urine levels of methadone. N.Y. State J. Med. 73:1973;2773-2777.
48. Kreek M. J. Physiological implications of methadone treatment. Methadone treatment manual. 1973;85-91 US Government Printing Office, US Department of Justice Publ. No. 2700-00227. Washington, DC.
49. Kreek M. J. Methadone maintenance treatment for chronic opiate addiction. Richter R. Medical aspects of drug abuse. 1975;167-185 Harper & Row, New York.
50. Kreek M. J. Pharmacologic modalities of therapy. Methadone maintenance and the use of narcotic antagonists Stimmel B. Heroin dependency. Medical, economic and social aspects:1975;232-290 Stratton Intercontinental Medical Book Corp, New York.
51. Kreek M. J. Medical complications in methadone patients. Ann. N.Y. Acad. Sci. 311:1978;110-134.
52. Kreek M. J. Methadone disposition during the perinatal period in humans. Pharmacol. Biochem. Behav. 11(suppl.):1979;1-7.
53. Kreek M. J. Methadone in treatment. Physiological and pharmacological issues Dupont R. L., Goldstein A., O'Connell J. Handbook on drug abuse. 1979;57-86 NIDA-ADAMHA-DEW-ODAP Executive Office of the President, Washington, DC.
54. Kreek M. J. Metabolic interactions between opiates and alcohol. Ann. N.Y. Acad. Sci. 362:1981;36-49.
55. Kreek M. J. Medical management of methadone-maintained patients. Lowinson J. H., Ruiz P. Substance abuse clinical problems and perspectives. 1981;660-673 Williams & Wilkins, Baltimore.
56. Kreek M. J. Health consequences associated with use of methadone. Cooper J. R., Altman F., Brown B. S., Czechowicz D. Research in the treatment of narcotic addiction. State of the art:1983;456-482 US Government Printing Office, NIDA Monograph. DHHS Publ. No. (ADM) 83-1281. Baltimore.
57. Kreek M. J. Tolerance and dependence. Implications for the pharmacological treatment of addiction Harris:1986;48th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of The Committee on Problems of Drug Dependence. NIDA Research Monograph 76. DHHS Publ. No. (ADM) 87-1508. Rockville, MD: US Government Printing Office; 1987:53-61.
58. Kreek M. J. Multiple drug abuse patterns and medical consequences. Meltzer H. Y. Psychopharmacology. The third generation of progress:1987;1597-1604 Raven Press, New York.
59. Kreek, M. J.: Cocaine effects on neuroendocrine function: Relationships to opiate effects and implications for immunological function. In: Abstracts of the American College of Neuropsychopharmacology, San Juan, PR; 1988.
60. Kreek M. J. Multiple drug abuse patterns. Recent trends and associated medical consequences Mello N. K. In. Advances in substance abuse 4: Behavioral and biological research:1991;91-111 Jessica Kingsley Publishers Ltd, London.
61. Kreek M. J. Using methadone effectively. Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs Pickens R., Leukefeld C., Schuster C. R. Improving drug abuse treatment. 1991;245-266 US Government Printing Office, NIDA Research Monograph 106. Rockville, MD.
62. Kreek M. J. Rationale for maintenance pharmacotherapy of opiate dependence. O'Brien C. P., Jaffe J. H. Addictive states. 1992;205-230 Raven Press, Ltd, New York.
63. Kreek M. J. Effects of opiates, opioid antagonists, and cocaine on the endogenous opioid system. Clinical and laboratory studies Harris:1991;53rd. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc. NIDA Monograph 119. DHHS Publ. No. (ADM) 92-1888. Rockville, MD: US Government Printing Office; 1992:44-48.
64. Kreek M. J. The addict as a patient. Lowinson J. H., Ruiz P., Millman R. B., Langrod J. G. Substance abuse. A comprehensive textbook:1992;997-1009 Williams & Wilkins, Baltimore.
65. Kreek M. J. Epilogue. Medical maintenance treatment for heroin addiction, from a retrospective and prospective viewpoint State methadone maintenance treatment guidelines. 1992;255-272 Office for Treatment Improvement, Division for State Assistance, Lockland, MD.
66. Kreek M. J. Pharmacotherapy of addictive diseases. Harris:1992;54th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 132. DHHS Publ. No. (ADM) 93-3505. Rockville, MD: US Government Printing Office; 1993:83.
67. Kreek M. J. Long-term pharmacotherapy for opiate (primarily heroin) addiction. Opiate agonists Schuster C. R., Kuhar M. J. Pharmacological aspects of drug dependence. Toward an integrated neurobehavioral approach:1996;487-562 Springer-Verlag, Berlin.
68. Kreek M. J. Long-term pharmacotherapy for opiate (primarily heroin) addiction. Opiate antagonists and partial agonists Schuster C. R., Kuhar M. J. Pharmacological aspects of drug dependence. Toward an integrated neurobehavioral approach:1996;487-562 Springer-Verlag, Berlin.
69. Kreek, M. J.: Opiates, opioids and addiction. Mol. Psychol.; 1996, in press.
70. Kreek M. J., Hartman N. Chronic use of opioids and antipsychotic drugs. Side effects, effects on endogenous opioids and toxicity Ann. N.Y. Acad. Sci. 398:1982;151-172.
71. Kreek M. J., Culpepper-Morgan J. Neuroendocrine (HPA) and gastrointestinal effects of opiate antagonists. Possible therapeutic application Harris:1990;52nd. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the Committee on Problems of Drug Dependence. NIDA Research Monograph 105. DHHS Publ. No. (ADM) 91-1753. Rockville, MD: US Government Printing Office; 1991:168-174.
72. Kreek M. J., Dodes L., Kane S., Knobler J., Martin R. Long-term methadone maintenance therapy. Effects on liver function Ann. Intern. Med. 77:1972;598-602.
73. Kreek M. J., Garfield J. W., Gutjahr C. L., Giusti L. M. Rifampin-induced methadone withdrawal. N. Engl. J. Med. 294:1976;1104-1106.
74. Kreek M. J., Gutjahr C. L., Garfield J. W., Bowen D. V., Field F. H. Drug interactions with methadone. Ann. N.Y. Acad. Sci. 281:1976;350-370.
75. Kreek M. J., Oratz M., Rothschild M. A. Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. Gastroenterology. 75:1978;88-94.
76. Kreek M. J., Hachey D. L., Klein P. D. Stereoselective disposition of methadone in man. Life Sci. 24:1979;925-932.
77. Kreek M. J., Wardlaw S. L., Friedman J., Schneider B., Frantz A. G. Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man. Simon E., Takagi H. Advances in endogenous and exogenous opioids. 1981;364-366 Kodansha Ltd. Publishers, Tokyo.
78. Kreek M. J., Wardlaw S. L., Hartman N., Raghunath J., Friedman J., Schneider B., Frantz A. G. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33(suppl. I):1983;409-411.
79. Kreek M. J., Schaefer R. A., Hahn E. F., Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet. 5:1983;261-262.
80. Kreek M. J., Schneider B. S., Raghunath J., Plevy S. Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of cortisol and ACTH in humans. Abstracts of the Seventh International Congress of Endocrinology. International Congress Series 652. Amsterdam-Oxford-Princeton:1984;845. NJ: Excerpta Medica;
81. Kreek M. J., Raghunath J., Plevy S., Hamer D., Schneider B., Hartman N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides. 5:1984;277-278.
82. Kreek M. J., Raghunath J., Spagnoli D., Mueller D., Stubbs V., Paris P. Possible age-related changes in levels of beta-endorphin in humans. Alcohol Drug Res. 6:1986;117.
83. Kreek M. J., Khuri E., Fahey L., Miescher A., Arns P., Spagnoli D., Craig J., Millman R., Harte E. Long term follow-up studies of the medical status of adolescent former heroin addicts in chronic methadone maintenance treatment. Liver disease and immune status Harris:1985;47th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the Committee on Problems of Drug Dependence. NIDA Research Monograph 67. DHHS Publ. No. (ADM) 86-1448. Rockville, MD: US Government Printing Office; 1986:307-309.
84. Kreek M. J., Ochshorn M., Ferdinands L., O'Bryan L., Carty A. Hypothalamic-pituitary-adrenal axis (HPA) effects in humans of a new opioid antagonist nalmefene with mu and kappa receptor subtype activity. Abstracts of the 1987 INRC Conference:1987;. Adelaide, Australia;
85. 1-13 administration causes elevation of serum levels of prolactin in human subjects. Harris:1993;55th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 141. NIH Publ. No. 94-3749. Rockville, MD: US Government Printing Office; 1994:108.
86. LaForge K. S., Unterwald E. M., Kreek M. J. Structure and expression of the guinea pig preproenkephalin gene. Site-specific cleavage in the 3′ untranslated region yields truncated mRNA transcripts in specific brain regions Mol. Cell. Biol. 15:1995;2080-2089.
87. Maggos C. E., Spangler R., Zhou Y., Kreek M. J. Dopamine transporter mRNA levels in the rat substantia nigra and ventral tegmental area immediately following and at two days and ten days after 'binge' cocaine administration. Harris:1994;56th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 153. NIH Publ. No. 95-3883. Rockville, MD: US Government Printing Office; 1995:508.
88. Maggos C. E., Spangler R., Zhou Y., Ho A., Kreek M. J. Quantification of dopamine transporter mRNA in rat brain and modulations by dopamine receptor antagonists and cocaine. In. Harris, L. S., ed. Problems of drug dependence,. 1995:1996;57th. Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph. Rockville, MD: US Government Printing Office;, in press.
89. Maisonneuve I. M., Kreek M. J. Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats. An in vivo microdialysis study J. Pharmacol. Exp. Ther. 268:1994;916-921.
90. Maisonneuve I. M., Ho A., Kreek M. J. Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats. An in vivo microdialysis study J. Pharmacol. Exp. Ther. 272:1995;652-657.
91. Mestek A., Hurley J. H., Bye L. S., Campbell A., Chen Y., Tian M., Schulman H., Yu L. The human mu opioid receptor. Modulation of functional desensitization by both calcium/calmodulin-dependent protein kinase and protein kinase C J. Neurosci. 15:1995;2396-2406.
92. Meunier J. C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J. L., Guillemot J. C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 377:1995;532-535.
93. Mollereau C., Parmentier M., Mailleux P., Butour J. L., Moisand C., Chalon P., Caput D., Vassart G., Meunier J. C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 341:1994;33-38.
94. 8 methadone. J. Pharm. Sci. 71:1982;39-43.
95. Novick D., Kreek M. J., Des Jarlais D., Spira T. J., Khuri E. T., Raghunath J., Kalyanaraman V. S., Gelb A. M., Miescher A. Antibody to LAV, the putative agent of AIDS. parenteral drug abusers and methadone-maintained patients: Abstract of clinical research findings: Therapeutic:1985;47th. historical, and ethical aspects. In: Harris, L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of The Committee on Problems of Drug Dependence. NIDA Research Monograph 67. DHHS Publ. No. (ADM) 86-1448. Rockville, MD: US Government Printing Office; 1986:318-320.
96. Novick D. M., Khan I., Kreek M. J. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. U.N. Bull. Narcotics. 38:1986;15-25.
97. Novick D. M., Ochshorn M., Ghali V., Croxson T. S., Mercer W. D., Chiorazzi N., Kreek M. J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250:1989;606-610.
98. Novick D. M., Trigg H. L., Des Jarlais D. C., Friedman S. R., Vlahov D., Kreek M. J. Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J. Med. Virol. 29:1989;181-185.
99. Novick D. M., Richman B. L., Friedman J. M., Friedman J. E., Fried C., Wilson J. P., Townley A., Kreek M. J. The medical status of methadone maintained patients in treatment for 11-18 years. Drug Alcohol Depend. 33:1993;235-245.
100. Ochshorn M., Novick D. M., Kreek M. J. In vitro studies of methadone effect on natural killer (NK) cell activity. Israel J. Med. Sci. 26:1990;421-425.
101. Ochshorn-Adelson M. O., Novick D. M., Khuri E., Albeck H., Hahn E. F., Kreek M. J. Effects of the opioid antagonist naloxone on human natural killer cell activity in vitro. Israel J. Med. Sci. 30:1994;679-684.
102. Ochshorn-Adelson M., Bodner G., Toraker P., Albeck P., Ho A., Kreek M. J. Effects of ethanol on human natural killer cell activity. In vitro and acute, low-dose in vivo studies Alcohol Clin. Exp. Res. 18:1994;1361-1367.
103. Pert C. B., Snyder S. H. Opiate receptor. Demonstration in nervous tissue Science. 179:1973;1011-1014.
104. Piazza P. V., Maccari S., Deminiere J.-M., Le Moal M., Mormede M., Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. USA. 33:1991;2088-2092.
105. Piazza P. V., Deroche V., Deminiere J.-M., Maccari S., Le Moal M., Simon H. Corticosterone in the range of stress-induced levels possesses reinforcing properties. Implication for sensation-seeking behaviors Proc. Natl. Acad. Sci. USA. 90:1993;11738-11742.
106. Piazza P. V., Deminiere J.-M., Le Moal M., Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science. 245:1994;1511-1514.
107. Piazza P. V., Marinelli M., Jodogone C., Deroche V., Rouge-Pont F., Maccari S., Le Moal M., Simon H. Inhibition of corticosterone synthesis by metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration. Brain Res. 658:1994;259-264.
108. Ragavan V. V., Wardlaw S. L., Kreek M. J., Frantz A. G. Effect of chronic naltrexone and methadone administration on brain immunoreactive beta-endorphin in the rat. Neuroendocrinology. 37:1983;266-268.
109. Raynor K., Kong H., Yasuda K., Chen Y., Yu L., Bell G. I., Reisine T. Pharmacological characterization of the cloned kappa, delta and mu opioid receptors. Mol. Pharmacol. 45:1994;330-334.
110. Reinscheid R. K., Nothacker H. P., Bourson A., Ardati A., Henningsen R. A., Bunzow J. R., Grandy D. K., Langen H., Monsma F. J. Jr., Civelli O. Orphanin FQ. A neuropeptide that activates an opioid like G protein-coupled receptor Science. 270:1995;792-794.
111. Rosen M. I., McMahon T. J., Margolin A., Gill T. S., Woods S. W., Pearsall H. R., Kreek M. J., Kosten T. R. Reliability of sequential naloxone challenge tests. Am. J. Drug Alcohol Abuse. 21:1995;453-467.
112. Rosen M. I., McMahon T. J., Hammedi F. A., Pearsall H. R., Woods S. W., Kreek M. J., Kosten T. R. Effect of clonidine pretreatment on naloxone-precipiated opiate withdrawal. J. Pharmacol. Exp. Ther. 276:1996;1128-1135.
113. Schluger J., Porter M., Maniar N., Gunduz M., Ho A., Kreek M. J. Differential effects of two opioid antagonists on hypothalamic pituitary adrenal (HPA) axis function in normal controls. In. Harris, L. S., ed. Problems of drug dependence,. 1996:1997;58th. Proceedings of the Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph. Rockville, MD: US Government Printing Office;, in press.
114. 2-like dopamine receptor agonists. Science. 271:1996;1586-1589.
115. 3H]etorphine to rat-brain homogenate. Proc. Natl. Acad. Sci. 70:1973;1947-1949.
116. Simonin F., Befort K., Gaveriaux-Ruff C., Matthes H., Nappey V., Lannes B., Micheletti G., Kieffer B. The human delta-opioid receptor. Genomic organization, cDNA cloning, functional expression, and distribution in human brain Am. Soc. Pharmacol. Exp. Ther. 46:1994;1015-1021.
117. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., Mattei M.-G., Charron G., Bloch B., Kieffer B. Kappa-opioid receptor in humans. cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system Proc. Natl. Acad. Sci. USA. 92:1995;7006-7010.
118. Spangler R., Unterwald E. M., Branch A., Ho A., Kreek M. J. Chronic cocaine administration increases prodynorphin mRNA levels in the caudate putamen of rats. Harris:1992;54th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 132. DHHS Publ. No. (ADM) 93-3505. Rockville, MD: US Government Printing Office; 1993:142.
119. Spangler R., Unterwald E. M., Kreek M. J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Mol. Brain Res. 19:1993;323-327.
120. Spangler R., Zhou Y., Unterwald E., Yuferov V., Ho A., Kreek M. J. Kappa opioid receptor mRNA levels in the rat brain. Effects of dopamine antagonists and cocaine Regulatory peptides 54: North Falmouth:1994;25th. MA: Proceedings of the International Narcotics Research Conference (INRC);:283.
121. Spangler R., Zhou Y., Unterwald E. M., Kreek M. J. Opioid peptide and receptor mRNA levels in the rat brain determined by TCA precipitation of mRNA. cRNA hybrids Harris:1994;56th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 153. NIH Publ. No. 95-3883. Rockville, MD: US Government Printing Office; 1995:484.
122. Spangler, R.; Ho, A.; Zhou, Y.; Maggos, C.; Yuferov, V.; Kreek, M. J.: Regulation of kappa opioid receptor mRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA. Mol. Brain Res.; 1996, in press.
123. Spangler R., Zhou Y., Maggos C. E., Schlussman S., Ho A., Kreek M. J. Persistent preprodynorphin and kappa opioid receptor mRNA responses to cocaine occur acutely. Harris:1996;58th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph. Rockville, MD: US Government Printing Office; 1997.
124. Stimmel B., Kreek M. J. Pharmacologic actions of heroin. Stimmel B. Heroin dependency. Medical, economic and social aspects:1975;71-87 Stratton Intercontinental Medical Book Corp, New York.
125. Stimmel B., Kreek M. J. Dependence, tolerance and withdrawal. Stimmel B. Heroin dependency. Medical, economic and social aspects:1975;88-97 Stratton Intercontinental Medical Book Corp, New York.
126. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol. Toxicol. 32:1973;317-320.
127. Thompson R. C., Mansour A., Akil H., Watson S. J. Cloning and pharmacological characterization of rat mu opioid receptor. Neuron. 11:1993;903-913.
128. 2 dopamine receptors in rat brain as measured by PET. In. Harris, L. S., ed. Problems of drug dependence,. 1996:1997;58th. Proceedings of the Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph. Rockville, MD: US Government Printing Office;, in press.
129. Unterwald E. M., Horne-King J., Kreek M. J. Chronic cocaine alters brain mu opioid receptors. Brain Res. 584:1992;314-318.
130. Unterwald E. M., Cox B. M., Kreek M. J., Cote T. E., Izenwasser S. Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse. 15:1993;33-38.
131. Unterwald E. M., Rubenfeld J. M., Kreek M. J. Repeated cocaine administration upregulates κ and μ, but not δ, opioid receptors. NeuroReport. 5:1994;1613-1616.
132. Unterwald E. M., Rubenfeld J. M., Spangler R., Imai Y., Wang J. B., Uhl G. R., Kreek M. J. Mu opioid receptor mRNA levels following chronic naltrexone administration. Regulatory peptides 54: North Falmouth:1994;25th. MA: Proceedings of the International Narcotics Research Conference (INRC);:307-308.
133. Unterwald E. M., Ho A., Rubenfeld J. M., Kreek M. J. Time course of the development of behavioral sensitization and dopamine receptor upregulation during binge cocaine administration. J. Pharmacol. Exp. Ther. 270:1994;1387-1397.
134. Unterwald E. M., Rubenfeld J. M., Imai Y., Wang J.-B., Uhl G. R., Kreek M. J. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol. Brain Res. 33:1995;351-355.
135. Unterwald E., Rubenfeld J. M., Kreuter J., Kreek M. J. Mu opioid receptor mRNA levels following chronic administration of opioid ligands. Analgesia. 1:1995;805-806.
136. Volavka J., Cho D., Mallya A., Bauman J. Naloxone increases ACTH and cortisol levels in man. N. Engl. J. Med. 300(18):1979;1056-1057.
137. Volkow N. D., Fowler J. S., Wolf A. P., Schlyer D., Shiue C. Y., Alpert R., Dewey S. L., Logan J., Bendriem B., Christman D., Hitzemann R., Ilenn F. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry. 147:1990;719-724.
138. 2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 14:1993;169-177.
139. Wang J. B., Imai Y., Eppler C. M., Gregor P., Spviak C., Uhl G. R. Mu-opiate receptor. cDNA cloning and expression Proc. Natl. Acad. Sci. USA. 90:1993;10230-10234.
140. Wang J. B., Johnson P. S., Persico A. M., Hawkins A. L., Griffen C. A., Uhl G. R. Human μ opiate receptor, cDNA and genomic clones, pharmacologic
141. Wang J. B., Johnson P. S., Imai Y., Persico A. M., Ozenberger B. A., Eppler C. M., Uhl G. R. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett. 348:1994;75-79.
142. Wick M. J., Minnerath S. R., Lin X., Elde R., Law P. Y., Loh H. H. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta and kappa opioid receptors. Mol. Brain Res. 27:1994;37-44.
143. Xie G. X., Meng F., Mansour A., Thompson R. C., Hoverten M. T., Goldstein A., Watson S. J., Akil H. Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc. Natl. Acad. Sci. USA. 91:1994;3779-3783.
144. Yu J., Chait B. T., Toll L., Kreek M. J. Nociceptin in vitro biotransformation in human blood. Peptides. 17:1996;873-876.
145. Yuferov V. P., LaForge K. S., Spangler R., Maggos C. E., Kreek M. J. Guinea pig preprodynorphin mRNA. Primary structure and regional quantitation in the brain DNA Cell Biol. 15(12):1996;1105-1112.
146. Zhang J., Albeck H., Culpepper-Morgan J., Friedman J., Kreek M. J. Distribution of preproenkephalin mRNA in the gastrointestinal tract of the guinea pig. Clin. Res. 36:1988;402A.
147. Zhang J. S., Plevy S., Albeck H., Culpepper-Morgan J., Friedman J., Kreek M. J. Effects of age on distribution of preproenkephalin-like mRNA in the gastrointestinal tract of the guinea pig. Advances in the biosciences 75: St. Adele:1988;1989. Quebec, Canada: Proceedings of INRC Meeting; :349-350.
148. Zhou Y., Spangler R., LaForge K. S., Kreek M. J. Attenuation of the hypothalamic-pituitary-adrenal response to chronic "binge" pattern cocaine administration corresponds to decreased CRH mRNA in rat hypothalamus. Regulatory peptides 54: Cape Cod:1994;25th. MA: Proceedings of the International Narcotics Research Conference (INRC);:345-346.
149. Zhou Y., Spangler R., Ho A., LaForge K. S., Yuferov V., Unterwald E., Kreek M. J. Corticotropin-releasing hormone (CRH) mRNA diurnal rhythms in rat hypothalamus and frontal cortex and inhibition by dexamethasone. Harris:1994;56th. L. S., ed. Problems of drug dependence, : Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 153. NIH Publ. No. 95-3883. Rockville, MD: US Government Printing Office; 1995:114.
150. Zhou Y., Spangler R., LaForge K. S., Maggos C., Kreek M. J. Modulation of CRF-R1 mRNA in rat anterior pituitary by dexamethasone. Correlation with POMC mRNA Peptides. 17:1996;435-441.
151. Zhou Y., Spangler R., LaForge K. S., Maggos C. E., Unterwald E. M., Ho A., Kreek M. J. Regulation of POMC gene expression in rat pituitary, hypothalamus and amygdala by chronic administration of CRH, dex, and methadone. In. Harris, L. S., ed. Problems of drug dependence,. 1995:1997;57th. Proceedings of the Annual Scientific Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph. Rockville, MD: US Government Printing Office;, in press.
152. Zhu Y. S., Branch A. D., Robertson H. D., Huang T. H., Franklin S. O., Inturrisi C. E. Time course of enkephalin mRNA and peptides in cultured rat adrenal medulla. Mol. Brain Res. 12:1992;173-180.